Core Viewpoint - The company reported strong financial performance for the first half of 2025, with significant revenue and profit growth, indicating robust operational momentum and effective market strategies [1][2]. Financial Performance - In 25H1, the company achieved revenue of 2.7 billion yuan, representing a year-on-year increase of 62.2% - Net profit reached 750 million yuan, up 52.7% year-on-year - Adjusted net profit, excluding interest income, was 730 million yuan, reflecting a 69.6% increase [1]. Revenue Breakdown - The revenue from IND before and after was 41% and 59% respectively, consistent with the structure from 24H1, although the IND after revenue share slightly decreased compared to 24H1 - North America remained the largest region, contributing 52% to total revenue in 25H1, an increase of 2 percentage points from 24 - Europe accounted for 22% of revenue, surpassing China's 18%, driven by strong performance in overseas licensing, NewCo models, and M&A activities [1][2]. Profitability Metrics - The company's gross margin improved by 4.0 percentage points year-on-year to 36.1% in 25H1, compared to 30.6% in 24 - The increase in gross margin was attributed to higher capacity utilization in production lines, particularly in the DS/DP segments, and the rapid ramp-up of the new BCM2 L2 production line initiated in November 24 - The adjusted net profit margin (excluding interest income) rose by 1.2 percentage points year-on-year to 27.1% [1]. Project and Capacity Expansion - As of 25H1, the company had a total of 225 iCMC projects, with 37 new projects signed in the first half, marking a historical high - The company also signed 3 new PPQ projects, totaling 11 projects - The total uncompleted order amount reached 1.33 billion USD, up 57.9%, with new contract amounts increasing by 48.4%, particularly in North America [2]. Production Capacity - All production lines, including BCM1, BCM2 L1, BCM2 L2, DP1, and DP2, are operating at high capacity - The third conjugate agent production workshop, DP3, successfully completed GMP release by the end of July 25 - The new Singapore base achieved mechanical completion in June 25 and is entering the equipment and facility debugging phase, with GMP release expected in 26H1 [2]. Capital Expenditure - The company anticipates capital expenditures of 1.56 billion yuan for 25, with approximately 900 million yuan allocated to the Singapore base and about 450 million yuan to the Wuxi base - By 29, total capital expenditures are expected to exceed 7 billion yuan, supporting rapid growth through domestic and international capacity expansion [2]. Investment Outlook - The company is positioned as a leading global ADC CXO enterprise with a comprehensive R&D platform and a growing customer base and project count - Revenue projections for 25, 26, and 27 are 5.75 billion, 7.83 billion, and 10.17 billion yuan, respectively, with year-on-year growth rates of 42%, 36%, and 30% - Expected net profits for the same years are 1.6 billion, 2.26 billion, and 3.02 billion yuan, with growth rates of 50%, 41%, and 34% respectively, leading to a PE ratio of 53, 37, and 28 times [3].

Market Performance - The Hong Kong stock market continued its decline, with notable drops in several biotech companies [1] - Innovent Biologics (09969) fell by 11.19%, closing at 14.760, with a market capitalization of 26.021 billion and a year-to-date increase of 141.18% [2] - Rongchang Biologics (09995) decreased by 10.22%, with a latest price of 95.350 and a total market value of 53.74 billion, reflecting a year-to-date increase of 562.15% [2] - WuXi AppTec (02268) and WuXi Biologics (02269) experienced declines of 5.68% and 5.32%, respectively, with market caps of 89.818 billion and 1585.28 billion [2] - Other companies such as Fuhong Hanlin (02696) and Kelun-Biotech (06990) also saw declines of over 4% [1][2] Company Highlights - Innovent Biologics has shown a significant year-to-date performance increase of 141.18% despite the recent drop [2] - Rongchang Biologics has the highest year-to-date increase among the listed companies at 562.15% [2] - WuXi Biologics and WuXi AppTec have maintained strong year-to-date increases of 120.84% and 138.50%, respectively [2] - Fuhong Hanlin and Kelun-Biotech also reported substantial year-to-date increases of 205.49% and 199.33% [2]

Core Viewpoint - The Hong Kong biopharmaceutical stocks continued to decline, with significant drops in several key companies, indicating a bearish trend in the sector [1]. Group 1: Stock Performance - Innovent Biologics (09969) experienced a decline of 11.19%, with a latest price of 14.760 and a total market capitalization of 26.021 billion, despite a year-to-date increase of 141.18% [2]. - Rongchang Biologics (09995) fell by 10.22%, with a latest price of 95.350 and a market cap of 53.747 billion, showing a remarkable year-to-date increase of 562.15% [2]. - WuXi AppTec (02268) saw a decrease of 5.68%, with a latest price of 73.100 and a market cap of 89.818 billion, maintaining a year-to-date increase of 138.50% [2]. - WuXi Biologics (02269) dropped by 5.32%, with a latest price of 38.780 and a market cap of 158.528 billion, reflecting a year-to-date increase of 120.84% [2]. - Fuhong Hanlin (02696) declined by 4.42%, with a latest price of 72.400 and a market cap of 39.349 billion, showing a year-to-date increase of 205.49% [2]. - Kelun-Biotech (06990) decreased by 4.25%, with a latest price of 488.800 and a market cap of 113.981 billion, with a year-to-date increase of 199.33% [2]. - WuXi AppTec (02359) fell by 4.19%, with a latest price of 114.400 and a market cap of 339.275 billion, reflecting a year-to-date increase of 109.21% [2]. - Gendicine (09688) saw a decrease of 2.83%, with a latest price of 25.440 and a market cap of 28.432 billion, with a year-to-date increase of 21.72% [2]. - CanSino Biologics (09926) declined by 2.05%, with a latest price of 128.800 and a market cap of 118.643 billion, reflecting a year-to-date increase of 112.19% [2]. - Junshi Biosciences (01877) fell by 2.02%, with a latest price of 29.100 and a market cap of 29.877 billion, showing a year-to-date increase of 151.30% [2].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][8]. Core Insights - The company has demonstrated rapid growth in performance, with a revenue of 2.7 billion yuan in the first half of 2025, reflecting a year-on-year increase of 62.2%, and a net profit of 750 million yuan, up 52.7% [4][5]. - The company is a leading global ADC CXO enterprise with a comprehensive R&D technology platform, a growing customer base, and an increasing number of projects [8]. Company Overview - Latest closing price: 74.50 HKD - Total shares: 1.228 billion - Total market capitalization: 91.486 billion HKD - 52-week high/low: 78.55/18.52 HKD - Debt-to-asset ratio: 29.94% - Price-to-earnings ratio: 62.9 [3]. Financial Performance - In the first half of 2025, the company achieved a gross margin of 36.1%, an increase of 4.0 percentage points year-on-year, driven by improved capacity utilization and the rapid ramp-up of new production lines [5]. - The company’s adjusted net profit margin (excluding interest income) increased by 1.2 percentage points to 27.1% compared to the same period in 2024 [5]. Project and Capacity Expansion - As of the first half of 2025, the company had a total of 225 iCMC projects, with 37 new contracts signed, marking a historical high [6]. - The company’s production lines are operating at high capacity, with significant orders in reserve, and plans for further expansion in Singapore and Wuxi [7]. Revenue and Profit Forecast - Projected revenues for 2025, 2026, and 2027 are 5.754 billion, 7.826 billion, and 10.174 billion yuan, respectively, with year-on-year growth rates of 42%, 36%, and 30% [11]. - Expected net profits for the same years are 1.601 billion, 2.259 billion, and 3.018 billion yuan, with growth rates of 50%, 41%, and 34% [11].

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：2268） 股東特別大會之投票表決結果如下： WUXI XDC CAYMAN INC. 藥 明 合 聯 生 物 技 術 有 限 公 司* 於2025年10月9日舉行的股東特別大會之投票表決結果 董 事 會 宣 佈 ， 於 2025 年 10 月 9 日 舉 行 的 股 東 特 別 大 會 上 ， 股 東 特 別 大 會 通 知 中 所載的提呈決議案獲本公司股東以投票表決方式正式通過。 藥 明 合 聯 生 物 技 術 有 限 公 司 *（「 本 公 司 」）董 事（「 董 事 」）會（「 董 事 會 」）宣 佈 ， 於 2025年10 月9日舉 行之本公司股東特別大 會（「股東特別大會」）上， 股東特別大會 通 知 中 所 載 的 提 呈 決 議 案 獲 本 公 司 股 東 以 投 票 表 決 ...

Core Viewpoint - The Hong Kong biopharmaceutical sector experienced a significant decline, with major companies reporting substantial drops in stock prices, indicating a bearish trend in the market [1]. Group 1: Stock Performance - Innovent Biologics (099660) saw a decline of 11.54%, with a latest price of 16.640 and a market capitalization of 293.36 billion, despite a year-to-date increase of 171.90% [2]. - Rongchang Biologics (09995) dropped by 9.20%, priced at 108.600, with a total market value of 612.08 billion, and a remarkable year-to-date increase of 654.17% [2]. - Kelun-Biotech (06990) fell by 7.71%, with a latest price of 533.000 and a market cap of 1,242.88 billion, while still showing a year-to-date increase of 226.39% [2]. - Tigermed (03347) decreased by 6.86%, priced at 43.960, with a market capitalization of 378.51 billion and a year-to-date increase of 44.25% [2]. - WuXi AppTec (02268) experienced a decline of 6.22%, with a latest price of 77.650 and a market cap of 954.09 billion, maintaining a year-to-date increase of 153.34% [2]. - CanSino Biologics (09926) dropped by 5.15%, priced at 134.500, with a market capitalization of 1,238.94 billion, and a year-to-date increase of 121.58% [2]. - Other companies like Junshi Biosciences (01877) and BeiGene (06160) also reported declines, with respective decreases of 3.16% and 2.48% [2].

FF301 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02268 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | 0.00005 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | 0.00005 | USD | | 500,000 | 本月底法定/註冊股本總額： USD 500,000 第 1 頁 共 11 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港 ...

Core Insights - The report from CMB International highlights the release of the first batch of innovative pharmaceutical technology medical insurance payment incentive catalog by Zhejiang Province, which is expected to alleviate the challenges of innovative drugs entering hospitals [1] - Despite the Trump administration's announcement of a 100% tariff on imported innovative drugs, the overall impact on China's pharmaceutical industry chain is considered manageable, with a recommendation to monitor subsequent developments [1] - The upcoming ESMO conference in mid to late October is noted as a key event, with a focus on companies such as CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (688331.SH) that are expected to release significant data [1] Industry Summary - The Hong Kong pharmaceutical sector has shown relatively flat performance in September, but with increasing industry catalysts such as academic conferences and favorable policy implementations in October, a market rebound is anticipated [1] - The report recommends focusing on specific segments: 1) Innovative drugs: Companies like 3SBio (01530) and Eucure Biopharma-B (06996) have rich short-term catalysts and their valuations do not yet reflect the core value of major products; companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are considered significantly undervalued with clear long-term growth logic [1] 2) CXO: Leaders in this segment, such as WuXi AppTec (02268), are expected to benefit from high downstream demand and marginal recovery in financing [1]

Market Overview - The Hong Kong stock market opened positively in October, with the Hang Seng Index closing at 27,287.12 points, up 431.56 points, a rise of 1.61% [2] - The Hang Seng Tech Index closed at 6,682.86 points, increasing by 217.20 points, a gain of 3.36% [4] Company Highlights - Alibaba Group (09988.HK) saw its stock rise over 4% during the day, closing at HKD 183.1, with a final increase of 3.45%. JPMorgan raised its target price for Alibaba's Hong Kong stock to HKD 240, indicating over 30% potential upside based on the current closing price [4] - JPMorgan reported that Alibaba Cloud's revenue growth has accelerated for eight consecutive quarters, with a year-on-year increase of 26% expected in Q2 2025, driven by demand in generative AI across various sectors [6] Sector Performance - The semiconductor sector experienced significant gains, with SMIC (00981.HK) surging 12% to reach a new historical high. Other notable performers included Longi Green Energy (06869.HK) up over 10%, and Huagong Technology (06908.HK) and Hua Hong Semiconductor (01347.HK) both rising over 7% [6] - The overall semiconductor industry is projected to continue its long-term growth, driven by AI data center demand and domestic substitution trends [8] Other Notable Stocks - The technology sector saw widespread gains, with Kuaishou-W (01024.HK) up over 8%, Baidu Group-SW (09888.HK) up over 4%, and JD Group-SW (09618.HK) and Xiaomi Group (01810.HK) both rising over 3% [8] - Gold stocks also performed well, with China Silver Group (00815.HK) increasing over 30% and Zijin Mining International (02259.HK) up over 14% [8] Industry Index Performance - The Wind Hong Kong secondary industry index showed significant increases in various sectors, with electrical equipment up 9.91%, non-ferrous metals up 5.29%, and hardware equipment up 4.70% [9]

Group 1 - Pharmaceutical stocks are experiencing a strong rally, with notable increases in share prices for companies such as Clover Biopharmaceuticals (up 20.26%), Genscript Biotech (up 15.05%), and others [1] - On September 26, former President Trump announced a 100% tariff on any brand or patented pharmaceutical products starting October 1, 2025, unless companies establish manufacturing facilities in the U.S. [1] - Southwest Securities predicts uncertainty regarding the implementation of this executive order, suggesting that Chinese innovative drug companies heavily reliant on the U.S. market may face short-term pressure [1] - China’s innovative drug companies that engage in business development (BD) overseas are expected to be less affected, particularly those involved in license-out agreements, which are essentially intellectual property transactions [1] - China Post Securities believes the actual impact of the tariffs will be minimal, viewing the current price drop as a good opportunity to increase holdings in innovative drugs [1] Group 2 - From the perspective of catalysts in the innovative drug sector, October will see significant industry conferences such as ESMO (October 17-21), followed by ASH and the San Antonio Breast Cancer Symposium in December [2] - There has been ongoing progress in outbound licensing transactions this year, with several significant deals already completed, indicating potential opportunities for high-quality domestic innovative drugs to enter international markets [2] - The fourth quarter is expected to bring domestic policy implementations, including adjustments to the medical insurance catalog [2]